US aid cuts threaten South Africa's status as powerhouse of HIV and tuberculosis research

South Africa risks losing its status as a powerhouse of HIV and tuberculosis research as sweeping American funding cuts jeopardise dozens of experimental trials.
At least 27 HIV trials and another 20 TB trials in the country have been put at risk by Donald Trump's deep cuts to foreign assistance and global health spending, new analysis shows.
Loss of the trials would hit research projects looking for new vaccines into both infections, as well as new long-lasting protective medicines and studies into the best way to treat children.
Having intense HIV and TB epidemics as well as world class universities and research institutes has made South Africa a leader in combating the two diseases.
Yet while the research has often been led by South African scientists, it has overwhelmingly been conducted with international funding, particularly with 20 years of generous United States government aid spending.
Prof Salim Abdool Karim, director of the Centre for the Aids Program of Research in South Africa, said: 'The US is such a big player in our country – South Africa is a powerhouse in medical research because of what the US spends.'
The bulk of funding for research came from the US National Institutes of Health (NIH), with the country receiving an estimated £111m ($150m) each year.
Prof Ntobeko Ntusi, the president and chief executive of the South African Medical Research Council (SAMRC), said earlier this year: 'In many ways the South African health research landscape has been a victim of its own success, because for decades we have been the largest recipients of both [official development assistance] funding from the US for research [and] also the largest recipients of NIH funding outside of the US.'
Now, unless alternative sources of money can be found, South African academic and research institutes could lose about 30 per cent of their annual income and may be forced to lay off hundreds of staff, the analysis found.
'There's been a huge dependence on US funding. The loss of it for South Africa means the cancellation of a huge amount of research,' said Tom Ellman, director of the MSF's Southern Africa Medical Unit (SAMU).
The joint analysis by Treatment Action Group (TAG) and Doctors Without Borders (MSF) of NIH-funded research found 39 TB and HIV clinical research sites are under threat, placing at least 27 HIV trials and 20 TB trials at risk.
The effect of cuts could be wider still, with research also funded through other US channels, including the US President's Emergency Plan for Aids Relief (Pepfar), which has been slashed by Donald Trump's administration.
Global research 'in peril'
Lindsay McKenna, TB project co-director of TAG said: 'Public funding from the US government to South Africa is the scaffold on which pharmaceutical companies, philanthropies, and other governments invest in transformative TB and HIV science.'
'These ongoing funding disruptions by the US government don't just affect US-funded research projects, they put in peril a much wider ecosystem of global research.'
Dr Ellman said a combination of the infections found in South Africa, its research base and its strong grass roots activism had combined, with US funding, to make the country so prominent in research.
He said: 'For years, South Africa has spearheaded the research and development of critical innovative medical tools for the prevention, diagnosis, treatment and care of HIV and TB which have saved lives not just within South Africa's borders, but also in communities worldwide.'
The country has more HIV patients than any other, with an estimated 8 million currently infected and 105,000 deaths annually.
The high prevalence of HIV goes hand-in-hand with a high prevalence of tuberculosis, because TB takes advantage of patients' weakened immune systems. Tuberculosis is the biggest cause of death among those with HIV in South Africa, which recorded 54,000 TB deaths in 2023.
At the same time, the country has strong research institutions and universities, and a history of medical innovation, including conducting the first heart transplant in 1969.
Finally, the history of the apartheid struggle, and later the fight in the early 2000s to get antiretroviral drugs in the face of government AIDS denialism, has produced well-organised and politically-engaged health activists.
According to the joint analysis, HIV trials now at risk include studies into using broadly neutralising antibodies (bNAbs) to find a cure, and also trials into long-lasting anti-HIV preventative jabs.
The Brilliant Consortium, a collaboration of African researchers led by the SAMRC working to develop an HIV vaccine, lost all funding even as it was about to begin an early stage vaccine trial.
Dr Ellman said: 'I think it would be a disaster if we gave up on the hope of finding an effective vaccine for HIV. All of that has been done with South Africa and without access to South African research and communities, it's not going to be possible.'
The emergence of some resistance to antiretroviral drugs has also highlighted the importance of trials to find new drugs which can deal with the phenomenon.
HIV trials are also looking at honing and improving existing treatment regimes, as well as simplifying and rolling out expensive techniques first used in the developing world.
TB trials at risk include studies for new drugs and shorter, safer regimens for treatment and prevention.
The cuts have a ripple effect beyond individual trials, because they also weaken research infrastructure which is used and relied on by other funders.
That could have a knock-on effect on trials looking at new TB jab possibilities, including the promising new M72/AS01E vaccine candidate.
South Africa is now scrabbling for alternative sources of funding to try to salvage as many of the research projects as possible.
Dr Ellman said: 'We call on all potential donors to step up, as without sustained investment, we will never end these deadly epidemics.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

BBC News

an hour ago

• BBC News

Rare ducklings hatch at Chester Zoo

A group of rare ducklings have hatched at Chester Maccoa duck is one of Africa's rarest and most endangered duck the first time the species has ever been successfully bred at the say only around 5,000 of the ducks remain in the wild, with the latest surveys finding just 14 individuals in Kenya and fewer than 100 in Tanzania - prompting concern over the future of the conservationists say they hope the successful hatching will lead to more protection for the birds. Maccoa ducks are diving ducks often found in nutrient-rich wetland habitats, like freshwater wetlands and are known for their stiff tails and deep-blue species is listed as endangered on the International Union for the Conservation of Nature's (IUCN) Red List of Threatened degradation, water pollution and climate change have been blamed for the species decline. There are just twelve zoos in the world that look after Maccoa ducks. Andrew Owen, Head of Birds at Chester Zoo, said:"This success gives a real boost to the future of the species... These birds are facing rapid decline in the wild, so every hatchling really does count."

The Guardian

20 hours ago

• The Guardian

David Hopkinson obituary

My friend and former colleague David Hopkinson, who has died aged 89, was director of the Medical Research Council's human biochemical genetics unit at University College London from 1976 until its closure in 2000. Hoppy, as he was universally known, had joined the unit at its inception in 1962 because in an earlier, more junior, position he had been one of the first medical scientists to describe molecular differences in human enzymes, long before DNA sequence differences were known about. The unit was established to research the extent and significance of genetic variation to human health. As its head, Hoppy expanded its focus to gene mapping and disease genetics while also moving into the new science of gene cloning and DNA sequencing. Born in Chesterfield, Derbyshire, to Albert Hopkinson, an iron and steelworks foreman, and Lilian (nee Siddal), a dressmaker, he went to Chesterfield grammar school, which fostered his early interest in organic chemistry. After completing a natural sciences degree at Cambridge University he qualified in medicine at the London hospital in 1959, working there until he joined the human biochemical genetics unit three years later. Hoppy was recruited by its inaugural head, Prof Harry Harris, becoming his right-hand man responsible for many of the unit's innovative experimental approaches, including developing novel methods of enzyme detection and electrophoresis. The unit moved in 1965 from its initial base at King's College to UCL, where I joined the unit three years later to study for a PhD under Harris. Hoppy remained there for the rest of his career. He published widely, and played an important part in teaching and supervision, being made full professor of London University in 1990. Twenty five years after his retirement, his role as mentor is remembered with great warmth by his former staff and students. Hoppy read widely and appreciated drama and music. A practical man who took pleasure in manual labour, he was an accomplished gardener and delighted in propagating plants and growing vegetables. He also enjoyed summers hiking in the Swiss Alps, and was a keen birdwatcher. In retirement, he studied architecture and German, and gained a first-class degree in geology at the Open University. He also spent many years as a volunteer at Chilterns' Citizens Advice in Chesham, Buckinghamshire. He is survived by his second wife, Prof Yvonne Edwards, and by three children, Paul, Susan and Ian, from his first marriage, to Josephine (nee Manze), which ended in divorce, and four grandchildren.

Daily Mail​

21 hours ago

• Daily Mail​

African gay men blame President Trump for their recent HIV diagnoses after he cut prevention funding

Gay men in Africa are blaming President Trump's decision to cut funding for HIV /AIDS prevention for their diagnoses of the virus. The administration's sweeping cuts to foreign aid have reduced access to medications like Pre-Exposure Prophylaxis, or PrEP, which decreases the risk of contracting HIV by 99 percent. Emmanuel Cherem, 25, a gay men in Nigeria, told Reuters that he tested positive for HIV two months after losing access to the US-supplied drug. 'I blame myself... Taking care of myself is my first duty as a person,' he said. 'I equally blame the Trump administration because, you know, these things were available, and then, without prior notice, these things were cut off.' Echezona, 30, another gay man from Nigeria, told Reuters that he took PrEP pills daily for three years until he was told by a clinic worker that the drug was now only available to pregnant and lactating women. 'I just pray and wish that Trump actually changes his policy and everything comes back to normal so that the spread and transmission of the virus would be reduced,' he said. Trump issued an executive order on his first day in office that paused foreign development assistance for 90 days, while Secretary of State Marco Rubio signed a 'stop work order' to employees of the State Department's Office of Foreign Assistance. The department oversees the US Agency for International Development (USAID) and the President's Emergency Plan for AIDS Relief (PEPFAR), which have seen drastic cuts since Trump took office. The administration has defended its position, arguing that other countries need to shoulder the burden of providing aid. During South African President Cyril Ramaphosa's White House visit, Trump acknowledged that the foreign aid cuts have been 'devastating.' 'Hopefully a lot of people are going to start spending a lot of money,' Trump added. 'I've talked to other nations. We want them to chip in and spend money too, and we've spent a lot,' he continued. 'And it's a big - it's a tremendous problem going on in many countries. A lot of problems going on. The United States always gets the request for money. Nobody else helps.' Russell Vought, the director of the US Office of Management and Budget, echoed Trump's stance during a Congressional committee meeting in early June. He argued that African countries should take on the responsibility of fighting HIV/AIDS, alleviating the financial burden on the US. Vought added that some of the nonprofits facilitating HIV prevention programs 'are not geared toward the viewpoints of the administration.' The director's comments are in line with a waiver issued to PEPFAR programs on February 1 allowing prevention programs to restart only for pregnant mothers. Vulnerable populations, like members of the LGBTQIA+ community, sex workers, or injecting drug users, weren't included in the prevention measures. PEPFAR grants often covered the cost of clinics supplying PrEP at public health centers for these populations, which have suffered closures due to decreased funding. A spokesperson for the State Department told Reuters that PEPFAR-funded programs would continue to be reviewed for 'assessment of programmatic efficiencies and consistency with United States foreign policy.' Public health officials and activists fear that if Trump's hardline policy toward foreign aid stays consistent, HIV infections will continue in the region. Linda-Gail Bekker, an HIV expert at the University of Cape Town, said that African countries may not cover the expense of supplying the drug, leaving a gap for more diagnoses. 'It's as predictable as if you take your eye off a smoldering bushfire and the wind is blowing: a bushfire will come back,' she told Reuters. Countries like Malawi, Zimbabwe, and Mozambique were almost entirely dependent on US funding for HIV prevention measures, according to UNAIDS. Other countries, like Ethiopia, responded to the USAID funding cuts by introducing a new payroll tax to pay for HIV medication previously provided by US funding. Medical advancements for HIV prevention and treatment have progressed significantly in recent years. However, UNAIDS projects that gaps created by a lack of funding could see steps backward.